Clinical trial
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly…
NCT00689221 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00689221 |
|---|---|
| Title | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status |
| Official title | Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance… |
| Acronym | CENTRIC |
| Lead sponsor | EMD Serono, Industry |
| Collaborators | European Organisation for Research and Treatment of Cancer - EORTC Merck KGaA, Darmstadt, Germany Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma |
| Intervention type | Drug, Radiation |
| Interventions | Cilengitide, Temozolomide, Radiotherapy |
| Enrollment | 545 |
| Start date | Sep 1, 2008 |
| Primary completion | Nov 1, 2012 |
| Completion | Aug 1, 2013 |
| First posted | Jun 3, 2008 |
| Last update posted | Nov 4, 2014 |
| Countries | Germany, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: